Hsbc Holdings PLC Boosts Stock Holdings in Hims & Hers Health, Inc. $HIMS

Key Points

• HSBC Holdings increased its Hims & Hers Health stake by 150.6% in the first quarter, bringing its holdings to 84,159 shares valued at approximately $1.74 million. Institutional investors collectively own 63.52% of the company.
• Analyst sentiment remains mixed: four analysts rate HIMS a Buy, 11 rate it a Hold and one rates it a Sell. The consensus rating is Hold, with an average price target of $31.43.
• Hims & Hers reported a quarterly loss of $0.40 per share, missing the $0.04 consensus estimate, while revenue rose 3.8% year over year to $608.1 million. The stock opened at $28.10, well below its 52-week high of $70.43.

Hsbc Holdings PLC lifted its stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 150.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 84,159 shares of the company's stock after buying an additional 50,577 shares during the period. Hsbc Holdings PLC's holdings in Hims & Hers Health were worth $1,741,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Binnacle Investments Inc purchased a new position in shares of Hims & Hers Health in the third quarter worth $28,000. Silicon Valley Capital Partners purchased a new stake in Hims & Hers Health during the 3rd quarter valued at $48,000. Flagship Harbor Advisors LLC bought a new stake in Hims & Hers Health in the 4th quarter worth $28,000. Bogart Wealth LLC increased its position in shares of Hims & Hers Health by 235.8% in the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company's stock valued at $29,000 after acquiring an additional 632 shares during the period. Finally, EverSource Wealth Advisors LLC increased its position in shares of Hims & Hers Health by 273.7% in the second quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company's stock valued at $47,000 after acquiring an additional 687 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

HIMS has been the subject of a number of analyst reports. JPMorgan Chase & Co. dropped their target price on shares of Hims & Hers Health from $35.00 to $33.00 and set an "overweight" rating for the company in a report on Tuesday, May 12th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a $25.00 price target on shares of Hims & Hers Health in a research report on Tuesday, May 5th. Needham & Company LLC increased their price objective on Hims & Hers Health from $30.00 to $35.00 and gave the stock a "buy" rating in a report on Tuesday, May 12th. Weiss Ratings lowered Hims & Hers Health from a "hold (c)" rating to a "sell (d)" rating in a research report on Tuesday, May 12th. Finally, Canaccord Genuity Group boosted their target price on Hims & Hers Health from $32.00 to $40.00 and gave the company a "buy" rating in a research note on Wednesday, July 1st. Four equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $31.43.

Hims & Hers Health Price Performance

HIMS stock opened at $28.10 on Monday. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56. Hims & Hers Health, Inc. has a 1 year low of $13.74 and a 1 year high of $70.43. The firm has a 50-day moving average of $30.75 and a 200 day moving average of $26.28. The company has a market cap of $6.50 billion, a P/E ratio of -312.26, a PEG ratio of 79.05 and a beta of 2.35.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The firm had revenue of $608.10 million for the quarter, compared to analysts' expectations of $616.84 million. During the same quarter last year, the company posted $0.20 EPS. The firm's revenue was up 3.8% on a year-over-year basis. On average, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.03 EPS for the current year.

Insider Buying and Selling

In other Hims & Hers Health news, Director David B. Wells bought 48,400 shares of the company's stock in a transaction dated Tuesday, May 26th. The shares were purchased at an average price of $24.23 per share, for a total transaction of $1,172,732.00. Following the acquisition, the director owned 224,417 shares in the company, valued at approximately $5,437,623.91. This represents a 27.50% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Michael Chi sold 14,027 shares of the company's stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total transaction of $441,850.50. Following the completion of the sale, the chief operating officer directly owned 432,124 shares in the company, valued at $13,611,906. This represents a 3.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 83,126 shares of company stock valued at $2,711,339 over the last 90 days. 11.76% of the stock is currently owned by company insiders.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: The FDA panel’s favorable peptide recommendation could eventually broaden Hims & Hers’ addressable market and support its emerging peptide therapy business. FDA Panel Narrowly Backs Four Peptides — Hims & Hers Stock in the Spotlight
• Neutral Sentiment: Truist raised its price target on HIMS to $27 from $23, but kept a hold rating, suggesting the firm sees limited upside from current levels. Tickerreport.com
• Neutral Sentiment: Recent commentary and search interest have kept HIMS in focus, reflecting elevated trading attention around the FDA-driven peptide story. Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
• Negative Sentiment: The sharp pullback appears consistent with a sell-the-news move as traders locked in gains after the initial FDA-related spike, since the regulatory process is not finished. Why Is HIMS Stock Rallying 13% Today?
• Negative Sentiment: Insider selling and mixed hedge fund positioning may also weigh on investor sentiment, as many major holders reduced exposure in the latest quarter. Hims & Hers Health Slides as Traders Fade Peptide Rally

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.